Abhishek Chandra, Sheikh Murtuja, Nitesh Chauhan, Puspendra Kumar, Sanjar Alam, Surya Prakash
Ropinirole hydrochloride is a modern selective non-ergoline dopamine D2-like receptor agonist with affinity for D2, D3 and D4 receptor subtypes, indicated for the treatment of the signs and symptoms of Parkinson’s disease and moderate-to severe primary RLS (Restless Legs Syndrome). It has moderate in vitro affinity for the opioid receptors. Ropinirole HCl is weakly active at the 5-HT2, and D2 receptors and is said to have virtually no affinity for the 5-HT1, benzodiazepine, GABA, muscarinic, D1 and F-adrenoreceptors. Ropinirole is metabolized primarily by cytochrome P450 CYP1A2, and at doses higher than clinical, is also metabolized by CYP3A4. At doses greater than 24 mg, CYP2D6 may be inhibited, although this has only been tested in vitro. Ropinirole HCl is a highly water soluble drug. UV spectroscopic studies show that ropinirole HCl gives maximum absorbance at Imax 250nm. Ropinirole HCL has been characterized by HPLC method which was achieved on a C18(250 x 4.6mm) 5 – micron Hypersil BDS using a mobile phase consisting of a degassed mixture of 0.05m glacial acetic acid (2.85 ml of glacial acetic acid in 1000 mL of water) and acetonitrile (50:50) with a flow rate of 1.0 mL/min. The mobile phase showed most favorable chromatographic parameter for analysis. The detection of the constituent was done using UV detector at 250nm.The retention time of ropinirole HCl was found to be 3.566 minutes. Ropinirole HCl was further characterized on the basis of FTIR studies.